on ReproNovo SA
ReproNovo Secures $65 Million for Phase 2 Trials in Reproductive Health
ReproNovo, a company focusing on reproductive medicine and women's health, has successfully closed a $65 million Series A financing round. The round was led by Jeito Capital, with AXA IM Alts and M Ventures as co-leaders, alongside support from Ysios Capital and ALSA Ventures. The funds will enable the company to advance its Phase 2 clinical programs.
Founded in 2021, ReproNovo is tackling significant issues in reproductive health, such as male and female infertility and uterine health. The company is developing RPN-001 for male infertility and RPN-002 for managing adenomyosis. These therapies aim to address a lack of effective treatments in these areas.
Jean Marie Duvall, CEO of ReproNovo, emphasized the importance of innovative solutions to meet unmet medical needs. Investors highlighted their confidence in ReproNovo's experienced team and their commitment to transforming reproductive health therapies.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ReproNovo SA news